Latest Breaking News On - Andrew rybczynski - Page 5 : comparemela.com

Vaccine Approval Could Mark a Turning Point in CRE Price Discovery Buyers hoping to capitalize on distress may only have a small window of time to strike as long-term prospects for troubled assets begins to brighten. Investors hoping to cash in on a COVID-19 pricing discounts may see opportunities slip away as emergency-use approval of the first vaccine against in the virus was granted to Pfizer and with availability expected to grow as other firms gain approvals in the coming weeks and months.  The coming widespread distribution of vaccines could very well prove to be the long-awaited light at the end of the tunnel for some struggling assets. Many buyers in the market have been hoping to negotiate at least some COVID-19 discount on pricing, even a slight five percent to 10 percent discount based on weaker rent growth. “I think there could still be some deals made in that range, but the combination of the vaccine outlook combined with more and more active liquidity in de

United statesAndrew rybczynskiDavid bitnerSteve jellinekAmericas capital markets research at cushman wakefieldCostar groupAmericas capital markets researchOxford economicsCostar risk analyticsGreat recessionCommercial repeat sales indexDean sigmonஒன்றுபட்டது மாநிலங்களில்ஆண்ட்ரூ றய்ப்க்ஜயின்ஸ்கிடேவிட் பிட்னர்அமெரிக்காக்கள் மூலதனம் சந்தைகள் ஆராய்ச்சி இல் குஷ்மேன் வேக்ஃபீல்ட்